{"id":"nortriptyline-lithium-nor-li","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Polyuria / polydipsia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nortriptyline is a tricyclic antidepressant that blocks the reuptake of norepinephrine at the presynaptic neuron, increasing its synaptic availability. Lithium augments this effect by inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), modulating second-messenger systems and neuroprotective pathways. This combination is used to enhance antidepressant efficacy and mood stabilization.","oneSentence":"Nortriptyline inhibits norepinephrine reuptake while lithium modulates intracellular signaling pathways, together enhancing monoaminergic neurotransmission and stabilizing mood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:48.773Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (particularly treatment-resistant depression)"},{"name":"Bipolar disorder depression"}]},"trialDetails":[{"nctId":"NCT00000375","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1997-02","conditions":"Major Depressive Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nortriptyline-lithium (NOR-Li)","genericName":"Nortriptyline-lithium (NOR-Li)","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nortriptyline inhibits norepinephrine reuptake while lithium modulates intracellular signaling pathways, together enhancing monoaminergic neurotransmission and stabilizing mood. Used for Major depressive disorder (particularly treatment-resistant depression), Bipolar disorder depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}